EGFR and neoplasm: In summary, ARID1A serves as the essential tumor suppressor in EGFR-mutant LUAD, while loss of ARID1A expression leads to the extensive activation of oncogenic pathways and enables tumor cells to acquire a more aggressive phenotype, finally resulting in the progression of the disease.